What is the prevalence of Guillain-Barré syndrome among individuals who have recovered from COVID-19?
Best insight from top research papers
The prevalence of Guillain-Barré syndrome (GBS) among individuals who have recovered from COVID-19 varies across studies. One study reported that out of 32 patients with GBS, 26 exhibited neurological symptoms after COVID-19 infection . Another study found that during the pandemic, 20% of GBS cases were associated with COVID-19 infection, while 16% were linked to COVID-19 vaccination . Additionally, a population-based study showed that three GBS cases were temporally associated with SARS-CoV-2 infection . These findings suggest that there is a notable but variable prevalence of GBS among individuals who have recovered from COVID-19, with some cases potentially linked to the infection or vaccination.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
| Not addressed in the paper. | |
| Approximately 20% of Guillain-Barré syndrome cases in the study were associated with prior COVID-19 infection, indicating a notable prevalence among individuals who have recovered from COVID-19. | |
| Not addressed in the paper. | |
| Not addressed in the paper. | |
| Not addressed in the paper. |
Related Questions
What's the prevalence of eating disorders post-covid?5 answersThe prevalence of eating disorders post-COVID has shown a significant increase among different populations. Studies have reported a rise in the prevalence of eating disorders in adolescents and young adults since the start of the pandemic, correlated with increased engagement with social media and negative body image. University students have also experienced a notable increase in the prevalence of eating disorders, with rates escalating from 31.8% to 51.8% in women and from 13.0% to 31.3% in men from 2018 to 2021. Furthermore, pediatric populations have faced increased rates of eating disorders during the pandemic, with clinicians noting a trend towards more referrals and hospitalizations. Additionally, a meta-analysis revealed a 57% prevalence of worsening eating disorder symptoms, 64% for anxiety, and 55% for depression among patients with eating disorders during the pandemic.
What are the neurological manifestations associated with COVID-19?4 answersNeurological manifestations associated with COVID-19 include dizziness, balance issues, anosmia, headaches, altered mental status, strokes, seizures, myalgia, hypogeusia, hyposmia, critical illness myopathy, visual disturbance, rhabdomyolysis, and nerve pain. These symptoms can persist for months after the infection has resolved and are more common in individuals under 60 years of age. Patients with preexisting medical conditions, such as cardiac disease, dementia, hypertension, and chronic obstructive pulmonary disease, are more likely to experience neurological manifestations. Additionally, individuals with Alzheimer's disease, Down syndrome, and those who have been hospitalized for COVID-19 are at a higher risk. Post-COVID neurological changes can also include memory difficulties, peripheral neuropathy, and dysautonomia. It is important to be aware of these manifestations to improve prognosis and provide appropriate diagnosis and treatment.
Do vaccinated individuals present lest post-COVID symptoms?5 answersVaccinated individuals have been found to present fewer post-COVID symptoms compared to unvaccinated individuals. Several studies have shown that post-vaccination infections are less likely to be symptomatic, with milder and fewer symptoms observed. Vaccination has been associated with a decreased risk of developing long COVID symptoms or being diagnosed with long COVID. In one study, individuals infected before vaccination had a higher proportion of post-acute sequelae of COVID-19 (PASC) symptoms compared to those infected after vaccination. Additionally, completing a primary vaccination sequence has been found to reduce the duration and frequency of symptoms, as well as post-COVID conditions. These findings highlight the effectiveness of vaccination in reducing the severity and impact of post-COVID symptoms.
What is known about Guillain-Barré syndrome (GBS) and the role of biomarkers? [1]?5 answersGuillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy that affects the peripheral nervous system. It is the most common cause of acute flaccid paralysis worldwide. The role of biomarkers in GBS has been investigated in several studies. One study found that peripheral neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), and platelet to lymphocyte ratio (PLR) may be indicators of disease activity in GBS patients, particularly those with severe disability. Another study used a multiplexing immunoassay to measure plasma cytokine levels in GBS patients and found that brain-derived neurotrophic factor (BDNF) may be a potential biomarker for the acute stage of GBS. Additionally, a review of GBS in China highlighted the need for a comprehensive understanding of the epidemiology, clinical characteristics, and risk factors of GBS, as well as the potential therapeutic effects of novel medications. Overall, biomarkers such as NLR, MLR, PLR, and BDNF may provide valuable insights into the progression and severity of GBS, aiding in diagnosis and treatment decisions.
How covid 19 related to neurological disorders?3 answersCOVID-19 is associated with various neurological disorders. Neurological symptoms have been observed in patients with COVID-19, including acute demyelinating syndromes, stroke, altered consciousness, seizures, and neuromyopathies.The incidence of these disorders following COVID-19 vaccination has also been reported, although the rate is relatively low.Pediatric patients with COVID-19 have been found to develop central nervous system acute demyelinating syndromes, such as Acute Disseminated Encephalomyelitis and Transverse Myelitis.COVID-19 can also lead to mental health disorders, with neuroinflammation and neuronal death being potential mechanisms.Patients with pre-existing neuromuscular disorders, such as myasthenia gravis, may experience complications related to COVID-19 infection.Further studies are needed to understand the pathogenesis and long-term effects of COVID-19 on the nervous system.
What is the symptom of neuropathy after COVID-19?3 answersNeuropathy after COVID-19 can present with symptoms such as hemiparesis, neuropathy, altered sensorium, weakness, fatigue, memory/attention deficits, sleep disturbances, myalgias, headache, and sleep disturbance. Laryngeal sensory neuropathy (LSN) can also occur, characterized by symptoms such as periodic hoarseness, sensation of a foreign body in the throat, and voice fatigue. Risk factors for developing prolonged neurological symptoms after COVID-19 include having depression, female gender, hospitalization, and usage of favipiravir. COVID-19 can also trigger lumbosacral radiculoplexus neuropathy (LRPN), which is a subacute, painful, paralytic, asymmetric immune-mediated lower-limb neuropathy associated with weight loss and diabetes mellitus.